drugset / Trial / NCT05512403

Evaluation of Diagnostic Performances of 18F-FDOPA PET KInetics

NCT05512403

Phase 3 Recruiting 88 enrolled Central Hospital, Nancy, France
NaSingle-groupOpen-labelDiagnostic

Summary

the investigators hypothesise that 18F-FDOPA PET kinetic parameters are good biomarkers to characterise suspected LGG brain lesions that exhibit no contrast on MRI, for identifying aggressive lesions. These parameters could constitute diagnostic biomarkers for this indication. This new diagnostic tool could enhance patient care in the short term in an evolving pathology affecting socially active subjects with a poor prognosis

Timeline

Start
2023-06-13
Primary completion
2025-12-12
Completion
2026-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-DOPA Diagnostic / imaging agent 2 mbq/kg

Indications